SARS-CoV-2 infection relaxes peripheral B cell tolerance

J Exp Med. 2022 Jun 6;219(6):e20212553. doi: 10.1084/jem.20212553. Epub 2022 Apr 14.

Abstract

Severe SARS-CoV-2 infection is associated with strong inflammation and autoantibody production against diverse self-antigens, suggesting a system-wide defect in B cell tolerance. BND cells are a B cell subset in healthy individuals harboring autoreactive but anergic B lymphocytes. In vitro evidence suggests inflammatory stimuli can breach peripheral B cell tolerance in this subset. We asked whether SARS-CoV-2-associated inflammation impairs BND cell peripheral tolerance. To address this, PBMCs and plasma were collected from healthy controls, individuals immunized against SARS-CoV-2, or subjects with convalescent or severe SARS-CoV-2 infection. We demonstrate that BND cells from severely infected individuals are significantly activated, display reduced inhibitory receptor expression, and restored BCR signaling, indicative of a breach in anergy during viral infection, supported by increased levels of autoreactive antibodies. The phenotypic and functional BND cell alterations significantly correlate with increased inflammation in severe SARS-CoV-2 infection. Thus, autoreactive BND cells are released from peripheral tolerance with SARS-CoV-2 infection, likely as a consequence of robust systemic inflammation.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Antibodies, Viral
  • B-Lymphocytes
  • COVID-19*
  • Humans
  • Inflammation / metabolism
  • Peripheral Tolerance*
  • SARS-CoV-2

Substances

  • Antibodies, Viral